Top 5 Drug Type | Count |
---|---|
Bispecific antibody | 17 |
Fusion protein | 8 |
Monoclonal antibody | 5 |
Tumor necrosis factors | 1 |
Antibody | 1 |
Target |
Mechanism CD19 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date31 Jul 2020 |
Mechanism Abl family inhibitors [+19] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date27 Sep 2012 |
Target |
Mechanism CD19 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date04 Apr 2024 |
Sponsor / Collaborator |
Start Date27 Dec 2023 |
Sponsor / Collaborator |
Start Date03 Aug 2023 |
Sponsor / Collaborator ![]() [+2] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Obexelimab ( CD19 ) | Autoimmune Diseases More | Phase 3 |
Izuralimab ( ICOS x PD-1 ) | Advanced Sarcoma More | Phase 2 |
Regorafenib ( Abl family x BRAF x BRAF V600E x CRAF x CSF-1R x DDR2 x EphA2 x FGFR1 x FGFR2 x FRK x MAPK11 x PDGFRα x PDGFRβ x RET x TRKA x Tie-2 x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit ) | Colorectal Cancer More | Phase 2 |
INB-03 ( TNF ) | COVID-19 More | Phase 2 |
Tafasitamab-Cxix ( CD19 ) | Acute Lymphoblastic Leukemia More | Phase 2 |